课题基金基金详情
基于TMA/FMO3/TMAO通路探讨丹蒌片治疗冠心病痰瘀互结证合并菌群失调大鼠的作用机制
结题报告
批准号:
81973600
项目类别:
面上项目
资助金额:
47.0 万元
负责人:
高晟
依托单位:
学科分类:
中西医结合临床基础
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
高晟
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
在我国,冠心病发病率及死亡率逐年上升,降低了冠心病患者生活质量并加重社会经济负担。前期研究表明:大部分冠心病患者存在菌群失调,以痰瘀互结证居多。国外研究显示ACVD患者肠道微生物健康状态的偏离会影响心血管的健康。TMA/FMO3/TMAO通路是调节炎症和脂质代谢的主要通路,肠道菌群可经过此通路将食物中的胆碱最终转化为TMAO,而TMAO集中作用于促进血小板聚集、影响胆固醇代谢、促进血管炎症反应,造成动脉粥样硬化而致冠心病。丹蒌片是临床常用治疗冠心病痰瘀互结证的中成药,疗效显著,现代药理研究已证实丹蒌片能调节高脂血症大鼠的脂代谢,明显缩小冠心病痰瘀互结证大鼠心肌梗死面积,减轻心肌组织和心肌细胞病理损伤。本研究选取SD大鼠作为实验对象,建立冠心病痰瘀互结证合并肠道菌群失调模型,给予不同剂量丹蒌片悬混液灌胃治疗,测量相关实验指标,研究丹蒌片是否能通过TMA/FMO3/TMAO通路影响肠道菌群。
英文摘要
In our country, the incidence of coronary heart disease, hospitalization rate and mortality are on the rising,causing a serious impact on the quality life of patients with coronary heart disease and social economy.Our previous study showed that a number of patients with coronary heart disease have intestinal flora inbalanced, in which patients with phlegm-stasis syndrome take the majority part. Foreign studies have shown that the deviation of the intestinal microbial health status of patients with ACVD will affect cardiovascular health. The TMA/FMO3/TMAO pathway is the main pathway regulating inflammation and lipid metabolism. The gut flora can ultimately convert choline of food into TMAO through this pathway.TMAO plays a central role in promoting platelet aggregation, affecting cholesterol metabolism and promoting vascular inflammation, resulting in atherosclerosis and coronary heart disease. As a commonly clinical Chinese medicine used in the treatment of phlegm-stasis syndrome of coronary heart disease, the effect of Dan-lou tables is significant,modern pharmacological studies have confirmed Dan-lou tables can regulate lipid metabolism of hyperlipidemic rats, significantly reduce myocardial infarction area of rats of phlegm-stasis syndrome of coronary heart disease and reduce myocardial tissue and myocardial cell pathological damage.In our study, SD rats were selected as experimental subjects, through the establishment of phlegm-stasis syndrome of coronary heart disease combined with intestinal flora imbalance model, giving different doses of Dan-lou tables suspension mixture gavage treatment and measuring relevant experimental indicators to explore whether intestinal flora can be affected by Dou-lou tables through TMA/FMO3/TMAO pathway.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.1159/000518727
发表时间:2021-09-14
期刊:EUROPEAN NEUROLOGY
影响因子:2.4
作者:Wang, Huimin;Zhang, Yanqiu;Gao, Sheng
通讯作者:Gao, Sheng
DOI:--
发表时间:2023
期刊:中国医药生物技术
影响因子:--
作者:史欣;高晟
通讯作者:高晟
DOI:10.1186/s12872-021-01960-4
发表时间:2021-03-24
期刊:BMC cardiovascular disorders
影响因子:2.1
作者:Han X;Wang H;Li Y;Liu L;Gao S
通讯作者:Gao S
DOI:10.1016/j.phyplu.2022.100266
发表时间:2022-03
期刊:Phytomedicine Plus
影响因子:--
作者:Han Guo;Sheng Gao;Yifan Zhu;Yuanqiang Guo;Zheng Hou;Yonggang Ma
通讯作者:Han Guo;Sheng Gao;Yifan Zhu;Yuanqiang Guo;Zheng Hou;Yonggang Ma
国内基金
海外基金